Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:2394:787-810.
doi: 10.1007/978-1-0716-1811-0_41.

Selection of Cancer Stem Cell-Targeting Agents Using Bacteriophage Display

Affiliations

Selection of Cancer Stem Cell-Targeting Agents Using Bacteriophage Display

Austin R Prater et al. Methods Mol Biol. 2022.

Abstract

There is a growing need to develop tumor targeting agents for aggressive cancers. Aggressive cancers frequently relapse and are resistant to various therapies. Cancer stem cells (CSCs) are believed to be the cause of relapse and the aggressive nature of many cancers. Targeting CSCs could lead to novel diagnostic and treatment options. Bacteriophage (phage) display is a powerful tool developed by George Smith in 1985 to aid in the discovery of CSC targeting agents. Phage display selections are typically performed in vitro against an immobilized target. There are inherent disadvantages with this technique that can be circumvented by performing phage display selections in vivo. However, in vivo phage display selections present new challenges. A combination of both in vitro and in vivo selections, however, can take advantage of both selection methods. In this chapter, we discuss in detail how to isolate a CSC like population of cells from an aggressive cancer cell line, perform in vivo and in vitro phage display selections against the CSCs, and then characterize the resulting phage/peptides for further use as a diagnostic and therapeutic tool.

Keywords: Bacteriophage; Biomarkers; Cancer stem cells; Characterization/target validation; Peptide-based tumor -targeting; Screening.

PubMed Disclaimer

References

    1. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29(34):4741 - DOI - PubMed - PMC
    1. Rich JN (2007) Cancer stem cells in radiation resistance. Cancer Res 67(19):8980–8984 - DOI - PubMed
    1. Eyler CE, Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol Off J Am Soc Clin Oncol 26(17):2839 - DOI
    1. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5(4):275 - DOI - PubMed
    1. Merlos-Suárez A et al (2011) The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8(5):511–524 - DOI - PubMed

Substances

LinkOut - more resources